R
Roland E. Schmieder
Researcher at University of Erlangen-Nuremberg
Publications - 780
Citations - 85811
Roland E. Schmieder is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Blood pressure & Essential hypertension. The author has an hindex of 97, co-authored 717 publications receiving 78138 citations. Previous affiliations of Roland E. Schmieder include Complutense University of Madrid & University of Regensburg.
Papers
More filters
Posted Content
Cost of poor adherence to anti-hypertensive therapy in five European countries
FS Mennini,Andrea Marcellusi,J.-M. Graf von der Schulenburg,Alastair Gray,Pierre Levy,Paolo Sciattella,M. Soro,Gianandrea Staffiero,Jan Zeidler,Aldo P. Maggioni,Roland E. Schmieder +10 more
TL;DR: This study is the first attempt to estimate the economic impact of non-adherence amongst patients with diagnosed hypertension in Europe, using data from five European countries (Italy, France, Germany, Spain and England), and suggests that increasing adherence to anti-hypertensive therapy to 70 % would save a total of €332 million.
Journal Article
Dihydropyridine calcium antagonists are associated with increased albuminuria in treatment-resistant hypertensives
Diana Hummel,Ulrike Raff,Thomas K. Schwarz,Markus P. Schneider,Roland E. Schmieder,Bernhard Schmidt +5 more
TL;DR: The data indicate that even in patients treated with ACEI/ARBs DHPs are associated with increased albuminuria, which should influence the choice of antihypertensive drugs in hypertensive patients withalbuminuria.
Journal ArticleDOI
Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry.
Roland E. Schmieder,Anselm K. Gitt,Cornelia Koch,Peter Bramlage,Taoufik Ouarrak,Diethelm Tschöpe +5 more
TL;DR: Individualized glucose and BP targets were selected by treating physicians based on patient characteristics and overall comorbidity and it was indicated that the strictly targeted patient populations maintained lower overall HbA1c and SBP levels at 6 months.
Journal ArticleDOI
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial
Sverre E. Kjeldsen,Gordon T. McInnes,Giuseppe Mancia,Tsushung A. Hua,Stevo Julius,Michael A. Weber,Antonio Coca,Xavier Girerd,Kenneth Jamerson,Pierre Larochelle,Thomas M. MacDonald,Roland E. Schmieder,M. Anthony Schork,Reuven Viskoper,Jiri Widimsky,Alberto Zanchetti +15 more
TL;DR: It is concluded that valsartan compared with amlodipine reduces the risk of developing diabetes mellitus, particularly in hypertensive patients with the highest susceptibility for development of diabetes.
Journal ArticleDOI
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics
Brett R. Cowan,Alistair A. Young,Craig S. Anderson,Craig S. Anderson,Robert N. Doughty,Rungroj Krittayaphong,Eva Lonn,Thomas H. Marwick,Christopher M. Reid,Christopher M. Reid,John E. Sanderson,Roland E. Schmieder,Koon K. Teo,Angela Wadham,Stephen G. Worthley,Cheuk-Man Yu,Salim Yusuf,Garry L. Jennings +17 more
TL;DR: The ONTARGET/TRANSCEND cardiac MRI substudy protocol provides for a reliable assessment of the effects of telmisartan and ramipril, alone and in combination, on cardiac structural and functional parameters over a 2-year follow-up period.